Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity.
Type:
Application
Filed:
July 18, 2012
Publication date:
November 8, 2012
Applicant:
University of Iowa Research Foundation
Inventors:
Beverly L. Davidson, Alejandro Mas Monteys, Jodi L. McBride, Ryan Boudreau
Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.
Abstract: Disclosed are polynucleotides and polypeptides that are useful for assessing and modulating cell proliferation. The polynucleotides may comprise coding regions for RPA4 and RPA4/RPA32 hybrid polypeptides. The polynucleotides may be used in gene vectors for modulating cell proliferation in a patient in need thereof. Diagnostic methods related to assaying RPA4 expression in test samples in order to detect proliferating or cancerous cells also are disclosed.
Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a -GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.
Type:
Grant
Filed:
March 20, 2008
Date of Patent:
September 18, 2012
Assignee:
University of Iowa Research Foundation
Inventors:
James McLinden, Jinhua Xiang, Jack T. Stapleton
Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity.
Type:
Grant
Filed:
May 29, 2008
Date of Patent:
September 4, 2012
Assignee:
University of Iowa Research Foundation
Inventors:
Beverly L. Davidson, Alejandro Mas Monteys, Jodi L. McBride, Ryan Boudreau
Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.
Type:
Grant
Filed:
November 10, 2006
Date of Patent:
September 4, 2012
Assignees:
University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The United States of America, as represented by the Department of Health and Human Services
Inventors:
Arthur M. Krieg, Joel N. Kline, Dennis Klinman, Alfred D. Steinberg
Abstract: A device may include a first plate and a second plate, and a linkage system that attaches the first plate and the second plate to one another such that the plates are capable of translating relative to each other, and the plates are incapable of rotating relative to each other.
Type:
Grant
Filed:
April 30, 2009
Date of Patent:
August 28, 2012
Assignee:
University of Iowa Research Foundation
Inventors:
Jose Morcuende, Nicole M. Grosland, Kelly Jensen, Nicole Jensen, Robert Kruse
Abstract: The invention provides recombinant AAV vectors, at least one of which has heterologous terminal palindromic sequences, and methods of using those vectors.
Abstract: This invention provides a method and system for determining the number of bits to assign to a frequency range in a signal. The present invention is capable of bit allocation, with B total bits, among a plurality of N frequency ranges in time a time O(N log N), which is independent of the size of B. Embodiments of the present invention have many practical applications, including allocating bits among sub-channels in a multi-carrier communication system, and allocating bits among sub-bands in a signal representing digital multimedia, such as in JPEG or MPEG compressed files.
Abstract: Embodiments of the present invention provide methods for targeted inactivation of viral genomes. In one embodiment, zinc-finger proteins in which DNA binding sites are altered such that they recognize and bind different, desired DNA sequences contained in hepatitis B virus (HBV) and that include nuclease domains are used for inactivation. Other embodiments for targeted inactivation of viral genomes use small nucleic acid molecules, such as short micro-RNA molecules or short hairpin RNA molecules capable of mediating RNA interference (RNAi) against the hepatitis B virus.
Abstract: Battery electrodes with desirable discharge performance comprise manganese oxide and magnetic particles. Corresponding power cells have improved specific discharge capacities. Furthermore, magnetically modified manganese dioxide electrodes are found to have significantly improved cycling properties that suggest the possibility for improved performance in secondary batteries.
Abstract: Disclosed are self-hydrating membrane electrode assemblies (MEAs), including MEAs that have been magnetically modified, which comprises (i) a cathode comprising an electrically conducting material having a catalytic material on at least a portion of a first surface thereof, the catalytic material comprising an effective amount of at least one catalyst component and at least one ion conducting material; (ii) a separator adjacent to and in substantial contact with the first surface of the cathode and comprising an ion conducting material; and (iii) an anode adjacent to and in substantial contact with the surface of the separator opposite the cathode and comprising an electrically conducting material having a catalytic material on at least a portion of a surface thereof adjacent to the separator, the catalytic material comprising an effective amount of at least one catalyst component and at least one ion conducting material; wherein the separator permits water to pass from the first surface of the cathode to the
Type:
Grant
Filed:
October 15, 2003
Date of Patent:
July 24, 2012
Assignee:
University of Iowa Research Foundation
Inventors:
Johna Leddy, Wayne L. Gellett, Drew C. Dunwoody
Abstract: The invention provides methods and an apparatus useful for site-isolating reagents or catalysts during chemical reactions. The methods and apparatus are useful for carrying out cascade or domino reactions.
Type:
Grant
Filed:
June 2, 2009
Date of Patent:
July 24, 2012
Assignee:
University of Iowa Research Foundation
Inventors:
Ned Bowden, Michael Brett Runge, Alan Lee Miller, III
Abstract: The present invention is directed to nucleic acid molecules containing a loop sequence designed to circumvent exportin-5 mediated export, and methods using these novel molecules.
Abstract: Disclosed is an implantable microspectrometer for the reagentless optical detection of an analyte in a sample fluid. The microspectrometer comprises an optical sampling cell having a cell housing defining a fluid inlet port and a fluid outlet port, the fluid inlet port configured to receive an optical sampling fluid from a test subject; an electromagnetic radiation source in communication with a first portion of the optical sampling cell housing and configured to irradiate at least a portion of the optical sampling fluid with electromagnetic radiation; and an electromagnetic radiation detector in communication with a second portion of the optical sampling cell housing and configured to detect electromagnetic radiation emanating from the optical sampling cell. In use, the implantable microspectrometer can optically detect at least one parameter of an analyte contained within the optical sampling fluid in the absence of an added reagent.
Type:
Grant
Filed:
April 4, 2006
Date of Patent:
June 19, 2012
Assignee:
University of Iowa Research Foundation
Inventors:
Mark A. Arnold, Jonathon T. Olesberg, Chris Coretsopoulos
Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
Type:
Grant
Filed:
November 20, 2002
Date of Patent:
June 19, 2012
Assignees:
University of Iowa Research Foundation, Coley Pharmaceutical GmbH, Ottawa Health Research Institute
Inventors:
Heather L. Davis, Joachim Schorr, Arthur M. Krieg
Abstract: An object of complex three-dimensional configuration, such as an automotive vehicle body, is coated with a combination of a coating formulation and a photoactivated mixture containing active centers that have been produced prior to application. The two liquids can be intimately mixed prior to application to the object, or the coating formulation can be applied prior to the application of the photoactivated mixture. The coating formulation is cured by the active centers that have been produced prior to application.
Type:
Grant
Filed:
June 8, 2007
Date of Patent:
June 12, 2012
Assignees:
Toyota Motor Engineering & Manufacturing North America, Inc., University of Iowa Research Foundation
Inventors:
Cynthia G. Templeman, Eric M. Leonard, Beth Ann Ficek, Alec B. Scranton
Abstract: Methods and systems for image registration implementing a feature-based strategy that uses a retinal vessel network to identify features, uses an affine registration model estimated using feature correspondences, and corrects radial distortion to minimize the overall registration error. Also provided are methods and systems for retinal atlas generation. Further provided are methods and systems for testing registration methods.
Type:
Grant
Filed:
April 27, 2009
Date of Patent:
June 5, 2012
Assignee:
University of Iowa Research Foundation
Inventors:
Michael Abramoff, Meindert Niemeijer, Sangyeol Lee, Joseph Reinhardt
Abstract: The present invention is an apparatus and method for computing regional statistical distributions or characteristics of one or more quantitative measures over a mean anatomic space for one or more predefined populations and uses this statistical distributions/characteristics to study, research or understand the regional response of a disease or a treatment process and to regionally assess clinical status in patient data from an unknown population for diagnostic purposes.
Type:
Grant
Filed:
February 15, 2008
Date of Patent:
May 29, 2012
Assignee:
The University of Iowa Research Foundation
Abstract: A novel isoform of tropomyosin is disclosed. The isoform is closely related to epithelial human tropomyosin (hTM) and more particularly to hTM5 except the last coding exon. The novel isoform, is called TC22. Northern blot analysis with TC22-specific probe revealed that normal culture cell lines and normal epithelial tissues expressed very little, if at all, TC22 message, whereas their transformed counterparts and tumor tissues including dysfunction of the alimentary canal, significantly increased the expression of TC22. Assays directed at determining the level of TC22 are useful in diagnostics and therapeutics of dysfunction of the alimentary canal. Specific antibodies and mimics for TC22 are also disclosed for use in diagnostics and therapeutics of dysfunction of the alimentary canal.
Type:
Grant
Filed:
October 23, 2009
Date of Patent:
June 12, 2012
Assignees:
University of Medicine and Dentistry of New Jersey, University of Iowa Research Foundation